Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2025 16:30 ET | Source: Rafael Holdings, Inc.

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced a rights offering, including key dates and terms. The planned offering is...
April 24, 2025 16:15 ET | Source: Rafael Holdings, Inc.

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from...
March 26, 2025 06:50 ET | Source: Rafael Holdings, Inc.

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business...
March 13, 2025 17:50 ET | Source: Rafael Holdings, Inc.

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo’s lead clinical program...
December 11, 2024 07:00 ET | Source: Rafael Holdings, Inc.

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

NEWARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the first quarter of fiscal year 2025 ended October 31, 2024. “We...
November 06, 2024 19:14 ET | Source: Rafael Holdings, Inc.

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

NEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024. ...
August 22, 2024 06:50 ET | Source: Rafael Holdings, Inc.; Cyclo Therapeutics

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from...
June 14, 2024 16:01 ET | Source: Rafael Holdings, Inc.

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

NEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30,...
March 13, 2024 17:04 ET | Source: Rafael Holdings, Inc.

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority...
December 14, 2023 16:01 ET | Source: Rafael Holdings, Inc.

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

NEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023....